Bovine lactoferrin for Helicobacter pylori eradication: An open, randomized, multicentre study

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 8, 2006, Pages 1235-1240

  Di Mario, F ^a   Aragona, G ^a   Dal Bo N ^b   Cavallaro, L ^a   Marcon, V ^c   Olivieri, P ^c   Benedetti, E ^d   Orzes N ^d   Marin, R ^d   Tafner, G ^e   Chilovi, F ^f   De Bastiani, R ^d   Fedrizzi, F ^d   Franceschi, M ^d   Salvat, M H ^b   Monica, F ^b   Piazzi, L ^f   Valiante, F ^d   Vecchiati, U ^c   Cavestro, G M ^a   Comparato, G ^a   Iori, V ^a   Maino, M ^a   Leandro, G ^g   Pilotto, A ^h   Rugge, M ⁱ   Franze A ^c   more..

^a UNIVERSITY OF PARMA   (Italy)

^b University of Treviso   (Italy)

^c Az Ospedaliera   (Italy)

^d Az Ospedaliera   (Italy)

^e Az Ospedaliera   (Italy)

^f Gastroenterology Unit   (Italy)

^g NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ESOMEPRAZOLE; LACTOFERRIN; TINIDAZOLE;

ADULT; AGED; ARTICLE; BITTER TASTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; ERADICATION THERAPY; FATIGUE; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CHI-SQUARE DISTRIBUTION; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOFERRIN; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; TINIDAZOLE; TREATMENT OUTCOME;

EID: 33646875068     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02851.x     Document Type: Article

References (37)

1. Malfertheiner P Mègraud F O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002 16 : 167 80.
2. Perri F Qasim A Marras L O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2003 8 Suppl. 1 S53 60.
3. Kihira K Satoh K Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 1083 7.
4. Van der Hulst RW Weel JF Van der Ende A Ten Kate FJ Dankert J Tytgat GN. Therapeutic options after failed Helicobacter pylori eradication therapy. Am J Gastroenterol 1996 9 : 2333 7.
5. Neville PM Barrowclough S Crocombe W Axon AT Wrangstadh M Moayyedi P. Randomised study of the efficacy of omeprazole and clarithromycin with either amoxycillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients. Dig Liver Dis 2001 33 : 131 4.
6. Bazzoli F Olivieri L De Luca L Pozzato P Lehours P Megraud F. Therapy and drug resistance in Helicobacter pylori infection. Dig Liver Dis 2000 32 Suppl. 3 0S207 10.
7. Gisbert JP Gisbert JL Marcos S Gravalos RG Carpio D Pajares JM. Seven-day rescue therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999 13 : 1311 6.
8. Lee JM Breslin NP Hyde DK Buckley MJ O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999 13 : 489 96.
9. Huang JQ Hunt RH. Treatment after failure: the problem of 'non-responders'. Gut 1999 45 Suppl. 1 140 4.
10. Gomollon F Sicilia B Ducons JA Sierra E Revillo MJ Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000 14 : 1335 8.
11. Cammarota G Cianci R Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 1339 43.
12. Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001 15 : 1543 47.
13. Baker EN Anderson BF Baker HM, et al. Structure, function and flexibility of human lactoferrin. Int J Biol Macromol 1991 13 : 122 9.
14. Wada T Aiba Y Shimizu K Takagi A Miwa T Koga Y. The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Scand J Gastroenterol 1999 34 : 238 43.
15. Britigan BE Serody JS Cohen MS. The role of lactoferrin as an anti-inflammatory molecule. Adv Exp Med Biol 1994 335 : 143 56.
16. Ellison RT. The effects of lactoferrin on gram-negative bacteria. Adv Exp Med Biol 1994 357 : 71 90.
17. Lonnerdal B Lyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995 15 : 93 110.
18. Levay P Viljoen M. Lactoferrin: a general review. Haematologica 1995 80 : 252 67.
19. Dial EJ Hall LR Serna H Romero JJ Fox JG Lichtenberger LM. Antibiotic properties of bovine lactoferrin in the host infected with Helicobacter pylori. Dig Dis Sci 1998 43 : 2750 6.
20. Dial EJ Lichtenberger LM. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 2002 80 : 113 7.
21. Pilotto A Rassu M Leandro G Franceschi M Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000 32 : 763 8.
22. Altintas E Sezgin O Ulu O Aydin O Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004 10 : 1656 8.
23. Sanchez L Calvo M Brock J. Biological role of lactoferrin. Arch Dis Child 1992 67 : 657 61.
24. Illingworth D Walter K Griffiths P Barclay R. Siderophore production and iron-regulated envelope proteins of Helicobacter pylori. Zentralbl Bakteriol 1993 280 : 113 9.
25. Singh PK Parsek MR Greenberg EP Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002 417 : 552 5.
26. Baldwin DA Jenny ER Aisen P. The effect of human serum transferrin and milk lactoferrin on hydroxyl radical formation from superoxide and hydrogen peroxide. J Biol Chem 1984 259 : 13391 4.
27. Gutteridge JM Paterson SK Segal AW Halliwell B. Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochem J 1981 199 : 259 61.
28. Jeremy B. Lactoferrin: a multifunctional immunoregulatory protein? Immunol Today 1995 16 : 417 9.
29. Mann DM Romm E Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J Biol Chem 1994 269 : 23661 7.
30. Zhang GH Mann DM Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 1999 67 : 1353 8.
31. Cole AM Dewan P Ganz T. Innate antimicrobial activity of nasal secretions. Infect Immun 1999 67 : 3267 75.
32. Jones EM Smart A Bloomberg G Burgess L Millar MR. Lactoferrin a new antimicrobial peptide. J Appl Bacteriol 1994 77 : 208 14.
33. Opekun AR El-Zaimaity HM Osato MS, et al. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 1999 13 : 35 42.
34. Husson MO Legrand D Spik G LeClere H. Iron acquisition by Helicobacter pylori: Importance of human lactoferrin. Infect Immun 1993 61 : 2694 7.
35. Di Mario F Aragona G Dal Bó N, et al. Use of lactoferrin for Helicobacter pylori eradication: preliminary results. J Clin Gastroenterol 2003 36 : 396 8.
36. Di Mario F Aragona G Dal Bó N, et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis 2003 35 : 706 10
37. Zullo F De Francesco V Scaccianoce G, et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicenter study. Dig Liv Dis 2005 37 : 496 500.